SUNNYVALE, Calif., May 4 /PRNewswire/ -- Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it will present an abstract demonstrating the utility of its Verisome Liquid Drug Delivery System in cystoid macular edema, at the Association for Research in Vision and Ophthalmology (ARVO) 2010 annual meeting, taking place May 2-6, 2010, in Fort Lauderdale, Florida.

Title: One Year Results of a Phase 1 Study Evaluating the Safety and Evidence of Efficacy of a Single Intravitreal Injection of the Verisome Liquid Drug Delivery System for Sustained Release of Low-Dose Triamcinolone (IBI-20089) in Eyes With Cystoid Macular Edema

Program Number: 6396

Session Date/Time: Thursday, May 6, 2010 from 1:15-3:00pm; Room Grand H

Session Title: Macular Edema Clinical Trials

About the Verisome Drug Delivery Technology

The Verisome drug delivery technology was invented by the Founder of Icon Bioscience, Inc., Vernon G. Wong, MD. The technology encompasses over 20 related, but distinct, novel and proprietary drug delivery systems. Highly versatile, it is capable of incorporating a broad range of active agents including small molecules, proteins and monoclonal antibodies and can deliver drugs in a controlled release manner for up to a year with a single injection.

About Icon Bioscience, Inc.

Icon Bioscience, Inc., (IBI), is a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals based on its Verisome drug delivery technology. IBI is developing a broad portfolio of clinically superior specialty pharmaceuticals targeting major ophthalmic indications including macular edema, glaucoma, age-related macular degeneration and cataract surgery inflammation. In addition to IBI-10090, which will begin pivotal clinical trials in the next few months, IBI-20089 has completed its initial clinical trial in patients with cystoid macular edema associated with retinal vein occlusion. It is designed to deliver triamcinolone for up to a year with a single intravitreal injection. IBI anticipates two more products will enter clinical trials in early 2011. IBI has also entered into agreements with multiple international pharmaceutical companies interested in the use of the Verisome technology for its own ophthalmic products. For more information please refer to www.iconbioscience.com

SOURCE Icon Bioscience, Inc.